Inventiva (IVA) Stock Price, Quote, News & History

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Name

Revenue

Change

Gross

Change

EBITDA

Change

EBIT

Change

Earnings

Change

About

Sector

Health Care

Industry

Biotechnology

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for ...

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Name

Revenue

Change

Gross

Change

EBITDA

Change

EBIT

Change

Earnings

Change

About

Sector

Health Care

Industry

Biotechnology

Bulls vs Bears

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Benzinga

Benzinga

Inventiva SA (IVA) Stock Price, Quote, News & History

Key Statistics

Recent Inventiva SA News

PROInventiva Reports Preliminary 2025 Financial Results With €99.3M Cash, €131.6M Short-Term Deposits And €4.5M Revenues, Runway Into Q1 2027

PROBarclays Initiates Coverage On Inventiva with Overweight Rating, Announces Price Target of $18

PROInventiva shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $12 price target.

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About

Edge Rankings

Stock Score Locked: Want to See it?

Compare

FAQ

How do I buy Inventiva (IVA) stock?

Who are Inventiva (IVA) competitors?

What is the forecast, or price target, for Inventiva (IVA) stock?

What is the current price for Inventiva (IVA)?

Does Inventiva (IVA) pay a dividend?

When is Inventiva (NASDAQ:IVA) reporting earnings?

Is Inventiva (IVA) going to split?

What sector and industry does Inventiva (IVA) operate in?

People Also Watch

Key Statistics

Recent Inventiva SA News

PROInventiva Reports Preliminary 2025 Financial Results With €99.3M Cash, €131.6M Short-Term Deposits And €4.5M Revenues, Runway Into Q1 2027

PROBarclays Initiates Coverage On Inventiva with Overweight Rating, Announces Price Target of $18

PROInventiva shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $12 price target.

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About

Edge Rankings

Stock Score Locked: Want to See it?

Bulls vs Bears

Compare

FAQ

How do I buy Inventiva (IVA) stock?

Who are Inventiva (IVA) competitors?

What is the forecast, or price target, for Inventiva (IVA) stock?

What is the current price for Inventiva (IVA)?

Does Inventiva (IVA) pay a dividend?

When is Inventiva (NASDAQ:IVA) reporting earnings?

Is Inventiva (IVA) going to split?

What sector and industry does Inventiva (IVA) operate in?

People Also Watch

Bulls vs Bears

PRO
Inventiva Reports Preliminary 2025 Financial Results With €99.3M Cash, €131.6M Short-Term Deposits And €4.5M Revenues, Runway Into Q1 2027

PRO
Barclays Initiates Coverage On Inventiva with Overweight Rating, Announces Price Target of $18

PRO
Inventiva shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $12 price target.

PRO
Inventiva Reports Preliminary 2025 Financial Results With €99.3M Cash, €131.6M Short-Term Deposits And €4.5M Revenues, Runway Into Q1 2027

PRO
Barclays Initiates Coverage On Inventiva with Overweight Rating, Announces Price Target of $18

PRO
Inventiva shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $12 price target.